Heterocyclic 1,4 dihydropyridine derivatives

US5051432A · kind A · utility

Assignee

• Glaxo SpA · IT

Inventors

• Claudio Semeraro · Bresso, IT
• Dino Micheli · Carpi, IT
• Daniele Pieraccioli · Verona, IT
• Giovanni Gaviraghi · Verona, IT
• Alan David Borthwick · London, GB

Key dates

• Filing date: Sep 19, 1990
• Grant date: Sep 24, 1991
• Expiry date: Sep 19, 2010

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P9/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds are described of the formula ##STR1## wherein R.sub.1 and R.sub.4 independently represent a C.sub.1-4 alkyl group: PA1 R.sub.2 represents a group ##STR2## (where A is a bond or a methylene group and R.sub.7 is phenyl C.sub.1-4 alkyl; or R.sub.2 represents a group CH.sub.2 CH.sub.2 NR.sub.8 R.sub.9 (where R.sub.8 is hydrogen or C.sub.1-4 alkyl and R.sub.9 is C.sub.1-4 alkyl, phenyl C.sub.1-4 alkyl or benzoyl C.sub.1-4 alkyl); or R.sub.2 represents a C.sub.1-4 alkyl group substituted by nitrile. PA1 R.sub.3 represents a C.sub.1-6 straight or brached alkyl chain or alkoxy group; PA1 R.sub.5 represents a straight or branched chain C.sub.1-13 alkyl group or a C.sub.5-8 cycloalkyl group which may be substituted by a C.sub.1-3 alkyl substituent; PA1 R.sub.6 represents a halogen atom or a straight or branched C.sub.1-3 alkyl group. The compounds represented by formula (I) reduce intracellular calcium ion concentration by limiting transmembranal calcium ion influx and thus may be useful for the treatment of cardiovascular disorders such as hypertension.